Farallon Reports 7.4% Avalo Therapeutics Stake Held Through Its Funds

The investment manager reported shared voting authority over 3,974,000 beneficial shares and certified that it was not seeking control.

Share
Farallon Reports 7.4% Avalo Therapeutics Stake Held Through Its Funds

Farallon Capital Management reported a 7.4% beneficial stake in Avalo Therapeutics, which develops drugs for immune-mediated inflammatory diseases, in a passive SEC ownership disclosure filed Friday. The position covered 3,974,000 shares as of September 30.

The Funds Hold The Position

Farallon manages the investment partnerships that directly hold the Avalo securities. The manager reported shared voting authority over the full beneficial position, with no shares under its sole voting authority.

The funds are entitled to any dividends and the money from selling the securities. Farallon's managing members and senior managing members also reported beneficial ownership relating to those fund holdings; their entries describe the same position and are not separate holdings to add together.

The beneficial-ownership calculation includes securities acquirable within 60 days, counting them in both the holder's position and the share base. That treatment is part of how the reported percentage is measured.

Farallon certified its holdings were acquired and held through ordinary business activity, without a purpose or effect of changing or influencing Avalo's control.

Avalo's Lead Drug Is In Testing

Avalo's development work centers on blocking IL-1β, a protein involved in inflammation. Its lead candidate, abdakibart, is an antibody being studied in a mid-stage trial for hidradenitis suppurativa, a chronic inflammatory skin disease.

According to Avalo's annual report for the fiscal year ended December 31, 2025, the company-sponsored trial covers approximately 250 adults with moderate to severe disease. Trial sites span the United States, Canada, Australia, Turkey and several European countries.

Avalo holds an exclusive worldwide license to abdakibart from Eli Lilly. The biotechnology company has no medicines approved for sale and uses outside contract manufacturers because it has no manufacturing facilities. Its older drug programs are outside clinical development.

Avalo's market capitalization was $445 million as of 9:07 a.m. ET Friday.

The reported stake measures Farallon's funds' beneficial ownership as of September 30; Friday was the date the manager filed the disclosure.

Sources

More on Avalo Therapeutics

All Avalo Therapeutics (AVTX) coverage →